BNTC
BENITEC BIOPHARMA (BNTC) Posts $45.5M Annual Loss, Eyes Pivotal BB-301 Trial in 2027
The gene therapy developer closed fiscal 2026 with $180 million in cash, a fully enrolled high-dose cohort and FDA talks on a pivotal study design.
BNTC
Market-moving news on Benitec Biopharma (NASDAQ: BNTC): filings, earnings, deals and other events, from REDFILED.